Intrexon reported $73.16M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
Alaunos Therapeutics USD 1.52M 367K Jun/2026
Amgen USD 96.05B 409M Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 1.74B 373.76M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Intrexon USD 73.16M 77.88M Jun/2024
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
MacroGenics USD 318.68M 26.72M Sep/2026
MannKind USD 722.62M 9.69M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 114.23B 1.06B Sep/2026
Veracyte USD 1.57B 86.89M Sep/2026
Xencor USD 770.5M 45.54M Sep/2026